Vedolizumab-Induced Acne Fulminans: An Uncommon and Severe Adverse Effect.
Cutis
; 110(3): E19-E20, 2022 09.
Article
in En
| MEDLINE
| ID: mdl-36446123
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Acne Vulgaris
/
Antibodies, Monoclonal, Humanized
Limits:
Humans
Language:
En
Journal:
Cutis
Year:
2022
Document type:
Article
Country of publication:
United States